Tesamorelin
FDA-studied GHRH analog for visceral fat reduction and GH optimization research.
Description
Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid modification. It is the only FDA-approved treatment specifically targeting visceral adipose tissue reduction. Tesamorelin stimulates the pituitary gland to produce and release growth hormone in a physiological, pulsatile manner.
Clinical studies have demonstrated significant reductions in trunk fat and visceral adipose tissue (VAT) with Tesamorelin administration. It increases IGF-1 levels while maintaining a favorable safety profile. Research continues to explore its applications in metabolic health and body composition optimization. This compound is for research purposes only.
Related Products
Retatrutide
Triple GLP-1/GIP/Glucagon receptor agonist for next-gen metabolic research.
Tesamorelin + Retatrutide Stack
Dual-compound stack combining GHRH analog with triple receptor agonist.
Bacteriostatic Water (BAC Water)
Sterile bacteriostatic water for safe peptide reconstitution and research use.